These adverse reactions may or may not be caused by the study treatments. A lot
of research is needed to know whether a treatment causes an adverse reaction.
These adverse reactions have been, and will continue to be, reviewed together
with all of the available data for durvalumab and olaparib.
The websites listed at the end of this summary may have other information about
adverse reactions or other medical problems that happened during this study.
The results below are for the 152 out of 154 participants who got at least 1 dose
of study treatment.
Did any adverse reactions happen during this study?
Durvalumab and olaparib Durvalumab and placebo
(out of 76 participants) (out of 76 participants)
How many participants had adverse 72.4% (55) 60.5% (46)
reactions?
How many participants had serious 14.5% (11) 11.8% (9)
adverse reactions?
How many participants stopped 7.9% (6) 6.6% (5)
taking study treatment due to adverse
reactions?
What serious adverse reactions happened during this study?
The most common serious adverse reaction was having low levels of red blood
cells, also called anemia. The table below shows the most common serious
adverse reactions that happened in at least 2 participants during the study. There
were other serious adverse reactions, but these happened in fewer participants.
Most common serious adverse reactions
Durvalumab and olaparib Durvalumab and placebo
Serious adverse reaction (out of 76 participants) (out of 76 participants)
Low levels of red blood cells, also 3.9% (3) 1.3% (1)
called anemia
Fatigue 2.6% (2) 0.0% (0)
Stomach pain 1.3% (1) 1.3% (1)
9 | Clinical Study Results